NCT00305851

Brief Summary

This randomized phase III trial is studying how well music therapy works compared to listening and discussing books on tape in improving quality of life in young patients undergoing stem cell transplant. Music therapy or book discussion may improve quality of life in patients undergoing stem cell transplant. It is not yet known whether music therapy is more effective than book discussion in improving quality of life in patients undergoing stem cell transplant.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
118

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Apr 2006

Longer than P75 for phase_3

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 21, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 22, 2006

Completed
24 days until next milestone

Study Start

First participant enrolled

April 15, 2006

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 5, 2010

Completed
10.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2021

Completed
Last Updated

July 15, 2022

Status Verified

January 1, 2013

Enrollment Period

4.5 years

First QC Date

March 21, 2006

Last Update Submit

July 13, 2022

Conditions

Outcome Measures

Primary Outcomes (20)

  • Assess acute changes of Symptoms-related distress: Pain

    Illness-related distress will be measured by indicators of uncertainty in illness, symptom-related distress. Brief Symptoms Assessment is a self-reported measure capturing information on pain. Specifically, the instrument includes a 1-item pain numeric rating scale.

    Change from pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant

  • Assess acute changes of Symptoms-related distress: Anxiety

    Illness-related distress will be measured by indicators of uncertainty in illness, symptom-related distress. Brief Symptoms Assessment is a self-reported measure capturing information on anxiety. Specifically, the instrument includes a 5-item Anxiety scale.

    Change from pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant

  • Assess acute changes of Symptoms-related distress: Fatigue

    Illness-related distress will be measured by indicators of uncertainty in illness, symptom-related distress. Brief Symptoms Assessment is a self-reported measure capturing information on fatigue. Specifically, the instrument includes a 1-item fatigue visual analogue scale.

    Change from pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant

  • Assess acute changes of Symptoms-related distress: Mood

    Illness-related distress will be measured by indicators of uncertainty in illness, symptom-related distress. Brief Symptoms Assessment is a self-reported measures capturing information on mood. Specifically, the instrument includes a 1-item mood scale.

    Change from pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant

  • Assess changes in uncertainty in illness as assessed by the Mishel Uncertainty in Illness Scale

    Mishel Uncertainty in Illness Scale-Revised (MUIS-R) consists of two factors: Complexity and Ambiguity, with higher scores indicating a high level of uncertainty. Item responses are on a 5-point Likert-type scale (ranging from 5 = Strongly Agree to 1 = Strongly Disagree

    Change from baseline, immediately after completion of study treatment and 100 days post-transplant

  • Assess changes in the use of defensive coping

    Defensive Coping will be measured by three subscales of the Jalowiec Coping Scale-Revised (JCS): evasive, emotive, and fatalistic coping. JCS is a self-report, 0-3 point rating scale. The items are scored for both use and effectiveness.

    Change from immediately after completion of study treatment and 100 days post-transplant

  • Assess changes in the use of positive coping

    Three subscales of the Jalowiec Coping Scale-Revised will measure Positive Coping (JCS): confrontive, optimistic, and supportive.

    Change from immediately after completion of study treatment and 100 days post-transplant

  • Assess changes in communication with family as assessed by Parent-Adolescent Communication

    Parent Adolescent Communication (P-AC) self-report items are on 5-point Likert scales that assess adolescents' views regarding their perceptions and experience of communicating with each parent rated separately. The two subscales, Open Family Communication and Problems in Family Communication, respectively measure positive and negative aspects of communications within a family and are scored independently.

    Change from baseline, immediately after completion of study treatment, and 100 days post-transplant

  • Assess changes in adaptability or cohesion as assessed by FACES II

    Family Adaptability and Cohesion Scale II (FACES II) is a self-report scale using Likert response scales and measuring the 2 factors: Adaptability or cohesion

    Change from baseline, immediately after completion of study treatment, and 100 days post-transplant

  • Assess changes in perceived social support from friends

    Perceived Social Support from Friends (PSS-Fr) is a self-report scale using 3-point rating responses ranging from 0 to 2 designed to measure the extent to which individuals perceive that their needs for support, information, and feedback are fulfilled by friends.

    Change from baseline, immediately after completion of study treatment, and 100 days post-transplant

  • Assess changes in perceived social support from family

    Perceived Social Support from Family (PSS-Fa) is a self-report, 3-point response (Yes, No, I don't know) scale, designed to measure the extent to which individuals perceive that their needs for support, information and feedback are fulfilled by family.

    Change from baseline, immediately after completion of study treatment, and 100 days post-transplant

  • Assess changes in perceived social support from healthcare providers

    Perceived Social Support from Health Care Providers (PSS-HCP) is a self-report, 3-point rating scale adapted by Haase from items on the Perceived Social Support-Friends scales102 to correspond to health care provider relationships. Items indicate the extent to which individuals perceive their needs for support, information, and feedback are fulfilled by health care providers.

    Change from baseline, immediately after completion of study treatment, and 100 days post-transplant

  • Assess changes in Hope from stem cell transplantation (STC) experience:

    Measured by indicators of hope. Herth Hope Index (HHI) items are on a 4-point scale, ranging from 1 (strongly disagree) to 4 (strongly agree); higher summative scores indicate greater hope.

    Change from immediately after completion of study treatment, and 100 days post-transplant

  • Assess changes in Spiritual Perspective from stem cell transplantation (STC) experience

    Measured by indicators spiritual perspective. Reed Spiritual Perspective Scale (RSPS) is a one-factor scale that measures the saliency of spiritual beliefs and behaviors in the respondent's life.157 The response format is a 6-point Likert scale anchored with words describing the frequency of behaviors.

    Change from immediately after completion of study treatment, and 100 days post-transplant

  • Assess changes of Higher Resilience: Haase Adolescent Resilience in Cancer Scale

    Haase Adolescent Resilience in Cancer Scale measures resilience related to illness. The scale uses a 6-point Likert-type scale ranging form: 1 (strongly disagree) to 4 (strongly agree); higher summative scores indicate greater resilience. Validity of the scales was found in predictive correlations with self-esteem, self-transcendence, confidence/mastery and quality of life. In Haase's preliminary studies, alpha reliability coefficients were 0.84 - 0.86.

    Change from after completion of study treatment and 100 days post-transplant

  • Assess changes of Higher Resilience (self esteem, confidence, self-transcendence): NCS

    Nowotny Confidence Subscale (NCS) of the Nowotny Hope Scale is a self-report of confidence in one's own ability, which uses a 4-point Likert response format of strongly agree to strongly disagree

    Change from after completion of study treatment, and 100 days post-transplant

  • Assess changes of Higher Resilience (self esteem, confidence, self-transcendence): STS

    Reed Self-Transcendence Scale (STS) assesses activities and perspectives individuals engage in to expand their boundaries via 4-point Likert response scales

    Change from after completion of study treatment, and 100 days post-transplant

  • Assess changes in Higher Resilience (self esteem, confidence, self-transcendence): SES

    Rosenberg Self-esteem Scale (SES) measures attitudes toward one's self. Responses are on a 4-point Likert scale.

    Change from after completion of study treatment, and 100 days post-transplant

  • Assess changes in indicators of well-being and global quality of life: LASA Uniscale

    Measured by indicators of well-being and global quality of life.LASA Uniscale is a global QOL self-report one-item instrument: "Please score how you feel your life has been affected by the state of your health (any disease or treatment) during the last week".160 The item is adopted from the Southwest Oncology Group protocol, which adapted the scale from a linear analogue to categorical format with 5 response categories ranging from extremely unpleasant to normal (no change).

    Change from baseline, immediately after completion of study treatment, and 100 days post-transplant

  • Assess changes in indicators of well-being and global quality of life: IWB

    Measured by indicators of well-being and global quality of life. Index of Well-being (IWB) is a semantic differential scale describing present life using adjective extremes such as discouraging/hopeful.

    Change from baseline, immediately after completion of study treatment, and 100 days post-transplant

Secondary Outcomes (1)

  • Qualitatively describe the perception of helpfulness and meaningfulness of both the low-dose and TMV interventions for AYA and family members

    100 days post-transplant

Study Arms (2)

Arm I (counseling)

ACTIVE COMPARATOR

Patients undergo six 1-hour sessions twice a week for 3 weeks with a trained counselor in which they choose up to 3 books on CD and listen to the book and/or discuss their impressions and thoughts about the contents with the counselor. Patients are provided with a portable CD player to listen to the books during their hospitalization.

Procedure: Psychosocial Assessment and CareOther: Quality-of-Life Assessment

Arm II (counseling and music therapy)

EXPERIMENTAL

Patients undergo six 1-hour sessions twice a week for 3 weeks with a music therapist, designed specifically for the pre-transplant and acute phase of treatment. Phases of patient participation include song writing, recording the song with a digital accompaniment track, completing a video layout worksheet, taking photos or making drawings for the video, viewing clip art and pictures on a computer, and sharing the final video with family members and hospital staff.

Procedure: Music TherapyProcedure: Psychosocial Assessment and CareOther: Quality-of-Life Assessment

Interventions

Music TherapyPROCEDURE

Undergo therapeutic music video therapy

Arm II (counseling and music therapy)

Undergo books on tape therapy

Also known as: Psychosocial Care/Assessment
Arm I (counseling)Arm II (counseling and music therapy)

Ancillary studies

Also known as: Quality of Life Assessment
Arm I (counseling)Arm II (counseling and music therapy)

Eligibility Criteria

Age11 Years - 24 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Diagnosis of an oncology condition requiring allogeneic or autologous transplantation
  • Receiving or planning to receive a myeloablative treatment regimen and 1 of the following:
  • Marrow transplantation
  • Peripheral stem cell transplantation
  • Cord blood stem cell transplantation
  • Patients with cancers that do not usually occur in childhood/adolescent or young adult populations (e.g., breast or prostate cancer) are not eligible
  • Able to read and speak English
  • English does not need to be the primary language
  • Able to participate in the sessions as evaluated for alertness and engagement by the music therapist
  • No cognitive impairments that would make it difficult to participate in the intervention or complete questionnaires
  • Not married and not a parent
  • Concurrent therapy for pain control or relief of other symptoms allowed

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Children's Healthcare of Atlanta - Egleston

Atlanta, Georgia, 30322, United States

Location

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States

Location

Children's Oncology Group

Philadelphia, Pennsylvania, 19104, United States

Location

MeSH Terms

Conditions

Neoplasms

Interventions

Music TherapyPsychiatric Rehabilitation

Intervention Hierarchy (Ancestors)

Sensory Art TherapiesComplementary TherapiesTherapeuticsRehabilitationAftercareContinuity of Patient CarePatient CarePsychotherapyBehavioral Disciplines and ActivitiesHealth ServicesHealth Care Facilities Workforce and Services

Study Officials

  • Joan E Haase

    Children's Oncology Group

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 21, 2006

First Posted

March 22, 2006

Study Start

April 15, 2006

Primary Completion

October 5, 2010

Study Completion

March 31, 2021

Last Updated

July 15, 2022

Record last verified: 2013-01

Locations